Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research-Anti-Infectives

Volume 7

eBook: US $79 Special Offer (PDF + Printed Copy): US $134
Printed Copy: US $95
Library License: US $316
ISSN: 2452-3208 (Print)
ISSN: 2352-3212 (Online)
ISBN: 978-981-4998-10-9 (Print)
ISBN: 978-981-4998-09-3 (Online)
Year of Publication: 2021
DOI: 10.2174/97898149980931210701

Introduction

Frontiers in Clinical Drug Research – Anti infectives is a book series that brings updated reviews to readers interested in learning about advances in the development of pharmaceutical agents for the treatment of infectious diseases. The scope of the book series covers a range of topics including the chemistry, pharmacology, molecular biology and biochemistry of natural and synthetic drugs employed in the treatment of infectious diseases. Reviews in this series also include research on multi drug resistance and pre-clinical / clinical findings on novel antibiotics, vaccines, antifungal agents and antitubercular agents. Frontiers in Clinical Drug Research – Anti infectives is a valuable resource for pharmaceutical scientists and postgraduate students seeking updated and critically important information for developing clinical trials and devising research plans in the field of anti infective drug discovery and epidemiology.

The seventh volume of this series features these interesting reviews:

- Nucleic acid and peptide aptamers as potential antiviral drugs

- Host-directed, antibiotic-adjuvant combination, and antibiotic-antibiotic combinations for treating multidrug-resistant (mdr) gram-negative pathogens

- Bioactive substances as anti-infective strategies against clostridioides difficile

- Anti-toxoplasma drug discovery and natural products: a brief overview

- Development of antimalarial and antileishmanial drugs from amazonian biodiversity

ADD A COMMENT

Your Rating *

RELATED BOOKS

.COVID 19 – Monitoring with IoT Devices.
.Recent Advances in the Application of Marine Natural Products as Antimicrobial Agents.
.Recent Trends and The Future of Antimicrobial Agents - Part 2.
.COVID-19: Origin, Impact and Management (Part 1).